Study S003297

A Randomized, Double-blind, Placebo-controlled Phase 2 Study of TG103 Injection in the Management of Non-diabetic Overweight or Obesity

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT06226090
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE2
Masking: DOUBLE
Status: COMPLETED
Enrollment: 314
Start: 2024-02-21
Primary completion: 2024-09-26
Lead sponsor: CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.
Conditions: Obesity; Overweight
Interventions: DRUG:TG103 7.5 mg; DRUG:Placebo 7.5 mg; DRUG:TG103 15 mg; DRUG:Placebo 15 mg; DRUG:TG103 22.5 mg; DRUG:Placebo 22.5 mg
Results posted: FALSE

Registered primary outcomes

Percentage relative change from baseline in body weight at week 24 [From baseline to week 24]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.